Literature DB >> 8348751

Elevated complement activities of sera from patients with high density lipoprotein deficiency (Tangier disease): the presence of normal level of clusterin and the possible implication in the atherosclerosis.

N H Choi-Miura1, T Sakamoto, S Ohtaki, H Nakamura, S Ishizawa, Y Takagi, K Gomi, M Tomita.   

Abstract

Clusterin (apolipoprotein J, SP-40,40), as well as apolipoprotein A-I (apo A-I) and apolipoprotein A-II (apo A-II), are apolipoprotein components of high density lipoprotein (HDL), but not of low density lipoprotein. In spite of the deficiencies of apo A-I, apo A-II and HDL in the sera of patients with Tangier disease, clusterin was found in them at normal level. While clusterin was present as the component of HDL with apo A-I in sera of normal donors, it was present as a protein which did not form a complex in sera of Tangier patients. SC5b-9 made from the sera of Tangier patients contained normal amounts of clusterin and was deficient in apo A-I, indicating that clusterin could be incorporated into the SC5b-9 complex without apo A-I. The complement activities of the sera of the patients were higher than those of normal donors. These results may be explained by the deficiencies of apo A-I, apo A-II and HDL in the patients, because they were suggested to be the inhibitors of the reactive haemolysis of complement. The elevated complement activities of the patients might be related to the severe atherosclerotic lesions in Tangier disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348751      PMCID: PMC1554838          DOI: 10.1111/j.1365-2249.1993.tb07973.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

Review 1.  Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis.

Authors:  M S Brown; J L Goldstein
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

2.  Tangier disease. In vitro conversion of proapo-A-ITangier to mature APO-A-ITangier.

Authors:  D Bojanovski; R E Gregg; H B Brewer
Journal:  J Biol Chem       Date:  1984-05-25       Impact factor: 5.157

3.  Ram rete testis fluid contains a protein (clusterin) which influences cell-cell interactions in vitro.

Authors:  I B Fritz; K Burdzy; B Sétchell; O Blaschuk
Journal:  Biol Reprod       Date:  1983-06       Impact factor: 4.285

4.  Comparative in vitro study of the pro-apolipoprotein A-I to apolipoprotein A-I converting activity between normal and Tangier plasma.

Authors:  C Edelstein; J I Gordon; C A Vergani; A L Catapano; V Pietrini; A M Scanu
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

5.  The activation of human complement component C5 by a fluid phase C5 convertase.

Authors:  R G DiScipio; C A Smith; H J Muller-Eberhard; T E Hugli
Journal:  J Biol Chem       Date:  1983-09-10       Impact factor: 5.157

6.  Tangier disease: defective recombination of a specific Tangier apolipoprotein A-I isoform (pro-apo A-i) with high density lipoproteins.

Authors:  G Schmitz; G Assmann; S C Rall; R W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

7.  Plasma apolipoprotein concentrations in familial apolipoprotein A-I and A-II deficiency (Tangier disease).

Authors:  P Alaupovic; E J Schaefer; W J McConathy; J D Fesmire; H B Brewer
Journal:  Metabolism       Date:  1981-08       Impact factor: 8.694

8.  A Japanese family with high density lipoprotein deficiency.

Authors:  S Ohtaki; H Nakagawa; N Kida; H Nakamura; K Tsuda; S Yokoyama; T Yamamura; S Tajima; A Yamamoto
Journal:  Atherosclerosis       Date:  1983-10       Impact factor: 5.162

9.  Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque.

Authors:  R Vlaicu; F Niculescu; H G Rus; A Cristea
Journal:  Atherosclerosis       Date:  1985-11       Impact factor: 5.162

10.  Tangier disease. High density lipoprotein deficiency due to defective metabolism of an abnormal apolipoprotein A-i (ApoA-ITangier).

Authors:  E J Schaefer; L L Kay; L A Zech; H B Brewer
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

View more
  3 in total

Review 1.  High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis.

Authors:  Scott M Gordon; Alan T Remaley
Journal:  Atherosclerosis       Date:  2016-11-16       Impact factor: 5.162

2.  Apolipoprotein J and Alzheimer's amyloid beta solubility.

Authors:  E Matsubara; C Soto; S Governale; B Frangione; J Ghiso
Journal:  Biochem J       Date:  1996-06-01       Impact factor: 3.857

3.  [A 52-year old female patient with recurrent shock of unclear origin, hemoconcentration and hypoalbuminemia].

Authors:  M Müller; A Schmidt
Journal:  Internist (Berl)       Date:  2004-05       Impact factor: 0.743

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.